Who are Biogen Inc.'s main suppliers?

Biogen Inc. (BIIB) key suppliers include: GENENTECH, EISAI, PURCHASER, United Community Banks, Inc., United Community Banks, Inc. and 3 more. View the full supplier network at chainsifter.com/chain/BIIB.

Who are Biogen Inc.'s major customers?

Biogen Inc. (BIIB) key customers include: APELLIS, SAMSUNG-BIOEPIS, SUPERNUS-PHARMACEUTICALS-INC, Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc. and 12 more. View the full customer network at chainsifter.com/chain/BIIB.

What sector is Biogen Inc. in?

Biogen Inc. (BIIB) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Biogen Inc. Supplier List (BIIB): 8 Verified Suppliers

8Suppliers

17Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Biogen Inc. (BIIB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

28Total relationships

2Distinct source URLs

11High confidence

0.735Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Biogen Inc. Suppliers

Ticker	Name	Confidence	Evidence
GENENTECH	GENENTECH	92%	Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities
EISAI	EISAI	90%	We currently have a supply agreement with Eisai to manufacture LEQEMBI drug substance and drug product through the end of 2031
PURCHASER	PURCHASER	90%	the Purchaser Board has recommended that the sole stockholder of Purchaser approve and adopt the Merger
UCB	United Community Banks, Inc.	80%	Reciprocal relationship from UCB graph: Reciprocal relationship from BIIB graph: A summary of development expense related to the UCB collaboration agreement is as follows
UCB	United Community Banks, Inc.	80%	A summary of development expense related to the UCB collaboration agreement is as follows
CCCC	C4 Therapeutics, Inc.	62%	Reciprocal relationship from CCCC graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from CCCC g…
RNAC	Cartesian Therapeutics, Inc.	62%	Reciprocal relationship from RNAC graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from RNAC graph: ns from June 2025 through May 2026. The funding was provided by NINDS to fur…
SRPT	Sarepta Therapeutics, Inc.	62%	Reciprocal relationship from SRPT graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from SRPT g…

Biogen Inc. Customers

Ticker	Name	Confidence	Evidence
APELLIS	APELLIS	92%	The Merger Agreement and the CVR Agreement and to consummate the Offer, the Merger and the other transactions contemplated by the Merger Agreement and the CVR Agreement, upon the terms and subject to…
SAMSUNG-BIOEPIS	SAMSUNG-BIOEPIS	85%	In exchange, we receive single-digit royalties on biosimilar products developed and commercialized by Samsung Bioepis
SUPERNUS-PHARMACEUTICALS-INC	SUPERNUS-PHARMACEUTICALS-INC	85%	We share 50.0 % of the net collaboration results in the U.S. with Supernus, which are recognized in collaboration profit sharing/(loss reimbursement)
APLS	Apellis Pharmaceuticals, Inc.	72%	Reciprocal relationship from APLS graph: Reciprocal relationship from BIIB graph: tensions in the Middle East, including the recent conflict involving the U.S., Israel and Iran, and the related regio…
APLS	Apellis Pharmaceuticals, Inc.	72%	tensions in the Middle East, including the recent conflict involving the U.S., Israel and Iran, and the related regional instability. The ongoing geopolitical conflicts in the region could lead to si…
SUPN	Supernus Pharmaceuticals, Inc.	72%	Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV Priority Review Voucher R&D Research and…
SUPN	Supernus Pharmaceuticals, Inc.	72%	Reciprocal relationship from SUPN graph: Reciprocal relationship from BIIB graph: Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum D…
ALCYONE-THERAPEUTICS-INC	ALCYONE-THERAPEUTICS-INC	62%	liferative glomerulonephritis, or primary IC-MPGN, in rare immune- 14 Table of Contents BIOGEN INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited, continued) mediat…
ALLOY-THERAPEUTICS-INC	ALLOY-THERAPEUTICS-INC	62%	plan injection) for the treatment of GA, an immune-mediated retinal disease; and EMPAVELI (pegcetacoplan) for the treatment of PNH, a rare blood disorder, and C3G and primary IC-MPGN in rare immune-m…
DEVELOPMENT-REATA-REATA-PHARMACEUTICALS-INC	DEVELOPMENT-REATA-REATA-PHARMACEUTICALS-INC	62%	Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV Priority Review Voucher R&D Research and…
HANGZHOU-CO-LTD	HANGZHOU-CO-LTD	62%	Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV Priority Review Voucher R&D Research and…
NEELA-THERAPEUTICS-INC	NEELA-THERAPEUTICS-INC	62%	$ 282.3 Royalty and other revenue 9.7 11.0 Total contract manufacturing, royalty and other revenue $ 246.9 $ 293.3 18 Table of Contents BIOGEN INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FI…
RARE	Ultragenyx Pharmaceutical Inc.	62%	Reciprocal relationship from RARE graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from RARE graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from RARE g…
RTP-RESEARCH-TRIANGLE-PARK-SAGE-SAGE-THERAPEUTIC	RTP-RESEARCH-TRIANGLE-PARK-SAGE-SAGE-THERAPEUTIC	62%	Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV Priority Review Voucher R&D Research and…
SAMSUNG-BIOEPIS-SAMSUNG-BIOEPIS-CO-LTD	SAMSUNG-BIOEPIS-SAMSUNG-BIOEPIS-CO-LTD	62%	Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV Priority Review Voucher R&D Research and…
SUPERNUS-SUPERNUS-PHARMACEUTICALS-INC	SUPERNUS-SUPERNUS-PHARMACEUTICALS-INC	62%	Nephropathy PNH Paroxysmal Nocturnal Hemoglobinuria PPACA Patient Protection and Affordable Care Act PPD Postpartum Depression PPMS Primary Progressive MS PRV Priority Review Voucher R&D Research and…
TJ-BIOPHARMA-CO-LTD	TJ-BIOPHARMA-CO-LTD	62%	plan injection) for the treatment of GA, an immune-mediated retinal disease; and EMPAVELI (pegcetacoplan) for the treatment of PNH, a rare blood disorder, and C3G and primary IC-MPGN in rare immune-m…

Biogen Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
BIIB-DEBT-8194	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2008-12-31.
BIIB-DEBT	Debt stack $6.3B	90%	Market cache reports total debt of $6.3B.

Biogen Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Biogen Inc..

Biogen Inc. Ownership

Holder	Name	Confidence	Evidence
BIIB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 1007 tracked holders.

Biogen Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
COLL	Collegium Pharmaceutical, Inc.	100.00	2
RARE	Ultragenyx Pharmaceutical Inc.	100.00	1	['customer']
UCB	United Community Banks, Inc.	100.00	1	['supplier']
SRPT	Sarepta Therapeutics, Inc.	100.00	1	['supplier']
CCCC	C4 Therapeutics, Inc.	100.00	1	['supplier']
SGIOF	Shionogi & Co., Ltd.	100.00	2
RNAC	Cartesian Therapeutics, Inc.	100.00	1	['supplier']
ZVRA	Zevra Therapeutics, Inc.	100.00	2
RGNX	REGENXBIO Inc.	50.00	2
ARTV	Artiva Biotherapeutics, Inc.	50.00	2
ORANY	ORANGE	50.00	2
ARWR	Arrowhead Pharmaceuticals, Inc.	50.00	2
CGEN	Compugen Ltd.	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
TKPHF	Takeda Pharmaceutical Company Limited	50.00	2
AZN	AstraZeneca PLC	50.00	2
TRDA	Entrada Therapeutics, Inc.	50.00	2
INCY	Incyte Corporation	50.00	2

Biogen Inc. Supply Chain